These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33302715)

  • 1. Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost.
    Dickert NW; Mitchell AR; Venechuk GE; Matlock DD; Moore MA; Morris AA; Pierce KJ; Speight CD; Allen LA
    Circ Cardiovasc Qual Outcomes; 2020 Dec; 13(12):e007070. PubMed ID: 33302715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan.
    Venechuk GE; Allen LA; Doermann Byrd K; Dickert N; Matlock DD
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006255. PubMed ID: 32814457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discussing Out-of-Pocket Costs With Patients: Shared Decision Making for Sacubitril-Valsartan in Heart Failure.
    Smith GH; Shore S; Allen LA; Markham DW; Mitchell AR; Moore M; Morris AA; Speight CD; Dickert NW
    J Am Heart Assoc; 2019 Jan; 8(1):e010635. PubMed ID: 30592239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy.
    Ioannou A; Metaxa S; Simon S; Mandal AKJ; Missouris CG
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):755-762. PubMed ID: 32648169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
    Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
    Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?
    Del Buono MG; Damonte JI; Trankle CR; Bhardwaj H; Markley R; Turlington J; Van Tassell BW; Salloum FN; Abbate A
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):331-333. PubMed ID: 34225338
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin Receptor Neprilysin Inhibitors-2019 Update.
    Chalikias G; Tziakas D
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):707-722. PubMed ID: 32519065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
    DeVore AD; Hill CL; Thomas L; Sharma PP; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Hernandez AF; Fonarow GC
    Circ Heart Fail; 2018 Sep; 11(9):e005400. PubMed ID: 30354360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.
    Mirić D; Baković D; Eterović D; Sorić T; Čapkun V; Vuković I; Duplančić D; Barac A
    J Cardiovasc Transl Res; 2021 Apr; 14(2):290-298. PubMed ID: 32557158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs.
    Rao BR; Akrobetu DJ; Dickert NW; Nguyen TV; Davis JK; Campagna A; Mitchell AR; Sharma A; Speight CD; Barks MC; Farley S; Gutterman S; Santanam T; Ubel PA
    J Am Heart Assoc; 2023 Apr; 12(7):e028278. PubMed ID: 36974764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM
    Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan: from a large clinical trial to clinical practice.
    Sciatti E; Senni M; Lombardi CM; Gori M; Metra M
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):473-479. PubMed ID: 29917003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
    Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions.
    Rao BR; Dickert NW; Morris AA; Speight CD; Smith GH; Shore S; Moore MA
    Circ Heart Fail; 2020 Nov; 13(11):e007094. PubMed ID: 33176459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
    Yandrapalli S; Andries G; Biswas M; Khera S
    Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.